Stem Cells and Advanced Cellular Therapies in Thailand: Regulatory Pathways, Real Challenges, and What Manufacturers Need to Know

Advanced Therapy Medicinal Products (ATMPs), including stem cell therapies, gene therapies, and tissue-engineered products, represent some of the most complex and highest-stakes products in the global pharmaceutical landscape. In Thailand, the regulatory framework for these products is developing with genuine ambition but real capacity constraints, and manufacturers face an environment that requires early, sustained regulatory engagement rather than the application-at-submission-stage approach that works for more established product categories.

The Current Regulatory Framework

Stem cell therapies and gene therapies in Thailand fall under the joint jurisdiction of the TFDA and the Medical Council of Thailand. The TFDA regulates cell-based therapeutic products as biologics under the Drug Act B.E. 2510, with specific guidance for ATMPs developed in stages since 2021. Manufacturing authorization for ATMP production requires a Drug Manufacturing License with specific annexes for biological products. GMP compliance must be demonstrated against standards referencing both WHO GMP Annex 2 (Manufacture of Biological Medicinal Products) and the EU's ATMP Regulation (EC) No 1394/2007, which serves as the primary international reference framework. The EU ATMP Regulation establishes requirements for quality, safety, and efficacy of gene therapy, somatic cell therapy, and tissue-engineered products — and Thailand's framework explicitly references it as a benchmark, which means manufacturers who have already navigated EU ATMP requirements will find their documentation framework largely applicable in Thailand.

The October 2024 Conditional Approval Pathway

In October 2024, the TFDA formalized a Conditional Approval mechanism for ATMPs demonstrating early clinical promise in treating serious conditions with significant unmet medical need. The pathway is modeled on the FDA's RMAT (Regenerative Medicine Advanced Therapy) designation and the EMA's PRIME (PRIority MEdicines) scheme. It allows manufacturers to access structured regulatory feedback earlier in the development process and can compress the pre-approval timeline for qualifying products by enabling rolling review of data as it becomes available rather than requiring a complete dossier at first submission. The pathway does not reduce evidence requirements: products approved conditionally are subject to post-approval confirmatory studies with defined timelines. What it provides is earlier, more structured engagement with the TFDA on development plans and data packages.

Real Challenges: Regulatory Capacity

The principal practical challenge for ATMP manufacturers in Thailand is not regulatory intent but regulatory capacity. The TFDA has a limited number of reviewers with specialized expertise to assess cell therapy manufacturing dossiers, gene therapy vector production data, and tissue-engineered product validation packages. This is not a criticism: ATMP regulation is genuinely specialized, and few regulators globally have deep ATMP expertise. The consequence is that review timelines for ATMP applications are long and unpredictable. Manufacturers who plan ATMP market entry in Thailand using pharmaceutical registration timelines as benchmarks consistently encounter delays. Planning a 24 to 36 month regulatory pathway from pre-IND engagement to conditional approval is realistic; planning for 12 months is not.

Clinical Trial Requirements

For manufacturers seeking to conduct clinical trials in Thailand as part of an ATMP development program, the TFDA's clinical trial authorization process for ATMPs involves both the TFDA and the Medical Council, and may require review by an expert committee for novel cell or gene therapy approaches. The Thailand FDA's requirements for clinical trial authorization align broadly with ICH E6 GCP and ICH E8, and Thailand's position as a clinical trial hub for Southeast Asia means that trial infrastructure and experienced investigator networks are available. For ATMPs specifically, trial site selection must account for the specialized handling and storage requirements of cell-based products, which are more demanding than small-molecule or conventional biologic clinical trial requirements.

What Manufacturers Should Do

Manufacturers developing or seeking to commercialize ATMPs in Thailand should engage with the TFDA regulatory pathway at the earliest possible stage, ideally before IND submission, to understand what evidence the TFDA will require and how to structure the development program accordingly. Pre-submission meetings with the TFDA's biologics division can clarify expectations and avoid costly late-stage development redirects. DeeMED Consulting provides regulatory strategy for advanced therapy manufacturers entering the Thai market, including pathway assessment, pre-submission meeting preparation, dossier structure planning, and TFDA engagement management throughout the development and approval process.